Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.47 |
| ▸ | WEE1 | P30291 | 5/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | BMX | P51813 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971255 | 0.90 | LCK (0.78) | LCKMAPK14FGFR1FGFR4WEE1 | |
| SCHEMBL3968867 | 0.79 | LCK (0.51) | LCKMAPK14FGFR1FGFR4WEE1 | |
| SCHEMBL3970398 | 0.79 | LCK (0.51) | LCKMAPK14FGFR1FGFR4WEE1 | |
| SCHEMBL6619817 | 0.78 | LCK (1.00) | LCKMAPK14FGFR1FGFR4WEE1 | |
| SCHEMBL6617874 | 0.78 | LCK (0.85) | LCKMAPK14FGFR1FGFR4WEE1 | |
| SCHEMBL3975918 | 0.78 | MAPK14 (0.53) | LCKMAPK14FGFR1FGFR4WEE1 | |
| SCHEMBL6619138 | 0.76 | LCK (0.74) | LCKMAPK14FGFR1FGFR4SRC | |
| SCHEMBL6622844 | 0.76 | LCK (0.86) | LCKMAPK14FGFR1FGFR4WEE1 | |
| SCHEMBL6619659 | 0.76 | LCK (0.91) | LCKMAPK14FGFR1FGFR4WEE1 | |
| SCHEMBL4208611 | 0.76 | FGFR4 (0.53) | LCKMAPK14FGFR1FGFR4WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | LCK 117/4885MAPK14 447/4885FGFR1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.